Notwithstanding encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. The insurers are typically erecting barriers to access, including high expense criteria and prior